Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction

• প্রধান লেখক: Naomi Chadderton (লেখক), Arpad Palfi (লেখক), Daniel M. Maloney (লেখক), Matthew Carrigan (লেখক), Laura K. Finnegan (লেখক), Killian S. Hanlon (লেখক), Ciara Shortall (লেখক), Mary O'Reilly (লেখক), Peter Humphries (লেখক), Lorraine Cassidy (লেখক), Paul F. Kenna (লেখক), Sophia Millington-Ward (লেখক), G. Jane Farrar (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2023-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

AAV gene therapy for ocular disease has become a reality with the market authorisation of Luxturna^TM for RPE65-linked inherited retinal degenerations and many AAV gene therapies currently undergoing phase III clinical trials. Many ocular disorders have a mitochondrial involvem...